Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Nonparametric Estimation from Incomplete Observations

1958 • 7,673 citations

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

2001 • 902 citations

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

1999 • 726 citations

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 • 654 citations

Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α

1999 • 618 citations

Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset

1998 • 576 citations

Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology Group

2001 • 289 citations

High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer

1998 • 275 citations

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

2000 • 249 citations

Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)

2005 • 218 citations

Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732

2005 • 185 citations

Properties of thalidomide and its analogues: Implications for anticancer therapy

2005 • 184 citations

Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer

2004 • 167 citations

High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer.

2002 • 74 citations

Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer:a Hoosier Oncology Group randomized study

2002 • 66 citations

The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression

2004 • 41 citations

Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron‐specific enolase or lactate dehydrogenase

2002 • 37 citations

A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report

2005 • 37 citations

Basic treatment considerations using chemotherapy for patients with small cell lung cancer

2004 • 35 citations

Imatinib in small cell lung cancer

2003 • 30 citations

A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC)

2002 • 15 citations

Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy.

2002 • 7 citations